Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific share option exercise by Mr. D S Redfern on December 1, 2011, involving the purchase of 1,009 Ordinary shares at a price of £9.51 per share under the Sharesave Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of a director's share transaction.
Investor Verification Checklist
- Verify the total number of shares held by Mr. D S Redfern following the exercise of 1,009 options.
- Confirm the current market price of GSK Ordinary shares relative to the £9.51 exercise price.
- Review the full annual report (Form 20-F) for comprehensive financial performance data for the period ending December 2011.